Ipilimumab: showing survival benefit in metastatic melanoma

Authors: Minchom, Anna; Young, Kate; Larkin, James

Source: Future Oncology, Volume 7, Number 11, November 2011 , pp. 1255-1264(10)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Ipilimumab is a fully humanized monoclonal antibody to cytotoxic T-lymphocyte-associated antigen 4. Data from preclinical and clinical studies have shown that ipilimumab can cause tumor regression in patients with metastatic melanoma with response rates of 5.8-22%. Phase III trials have demonstrated a benefit in median overall survival in the first-line setting in combination with dacarbazine versus dacarbazine alone (11.2 vs 9.1 months) and in the second-line setting in combination with gp100 versus gp100 alone (10.1 vs 6.4 months). The main toxicities of ipilimumab are immune related, most commonly skin and gastrointestinal. Bowel perforation and treatment-related deaths have occurred, although prompt use of steroids and other immunosuppressive agents can minimize this risk.

Keywords: CTLA-4 blockade; ipilimumab; metastatic melanoma

Document Type: Drug Evaluation

DOI: http://dx.doi.org/10.2217/fon.11.105

Affiliations: 1: 1The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK

Publication date: 2011-11-01

More about this publication?

Future Oncology provides a forum for a new era of cancer care as research efforts burgeon in this challenging area. The burden of disease is set to increase in our increasingly aged populations, but the available armamentarium is also set to grow rapidly and to offer the potential to focus on individual needs. The journal focuses on the most important advances and highlights their relevance in the clinical setting.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites